These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 10928168

  • 1. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T, Khalifa A, Kamel AS.
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [Abstract] [Full Text] [Related]

  • 2. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L, Baker H, Sinowatz F.
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E, Kamina S, Demou A, Kontostolis M, Lolis D, Agnantis NJ.
    Anticancer Res; 1999 Apr 12; 19(3A):2133-9. PubMed ID: 10470161
    [Abstract] [Full Text] [Related]

  • 5. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
    Shun CT, Wu MS, Lin JT, Chen SY, Wang HP, Lee WJ, Wang TH, Chuang SM.
    Hepatogastroenterology; 1997 Apr 12; 44(14):604-9. PubMed ID: 9164544
    [Abstract] [Full Text] [Related]

  • 6. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E, Kamina S, Athanassiadou S, Agnantis NJ.
    Anticancer Res; 1996 Apr 12; 16(5B):3141-7. PubMed ID: 8920782
    [Abstract] [Full Text] [Related]

  • 7. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD, Li MD, Li YF, Huang X, Liu JH, Liu FY, Zhang CQ.
    Ai Zheng; 2002 Mar 12; 21(3):292-6. PubMed ID: 12451998
    [Abstract] [Full Text] [Related]

  • 8. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
    Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR.
    Clin Cancer Res; 1999 Oct 12; 5(10):2682-8. PubMed ID: 10537329
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemical markers of tumor prognosis in breast cancer in Egypt.
    Helal T, Nassiri M, Khalifa A.
    Cancer Detect Prev; 1997 Oct 12; 21(3):201-6. PubMed ID: 9167036
    [Abstract] [Full Text] [Related]

  • 10. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M.
    J Urol; 2001 May 12; 165(5):1481-7. PubMed ID: 11342901
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ.
    Anticancer Res; 2000 May 12; 20(6B):4221-5. PubMed ID: 11205251
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
    Talley L, Chhieng DC, Bell WC, Grizzle WE, Frost AR.
    Biotech Histochem; 2008 Feb 12; 83(1):5-14. PubMed ID: 18568671
    [Abstract] [Full Text] [Related]

  • 13. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ, Aaltomaa S, Syrjänen S, Syrjänen K.
    Anticancer Res; 1993 Feb 12; 13(4):1147-52. PubMed ID: 8102517
    [Abstract] [Full Text] [Related]

  • 14. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE, Athanassiadou SE, Kamina S, Carassavoglou K, Agnantis NJ.
    Anticancer Res; 1998 Feb 12; 18(3A):1665-70. PubMed ID: 9673387
    [Abstract] [Full Text] [Related]

  • 15. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B, Parwaresch R.
    Hum Pathol; 2001 Mar 12; 32(3):311-9. PubMed ID: 11274641
    [Abstract] [Full Text] [Related]

  • 16. Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?
    Plastiras D, Moutzouris G, Barbatis C, Presvelos V, Petrakos M, Theodorou C.
    Eur J Surg Oncol; 1999 Feb 12; 25(1):61-5. PubMed ID: 10188857
    [Abstract] [Full Text] [Related]

  • 17. Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer.
    Barbati A, Cosmi EV, Sidoni A, Collini P, Porpora MG, Ferri I, Lüthy M, Lauro V, Bucciarelli E.
    Anticancer Res; 1997 Feb 12; 17(1A):401-5. PubMed ID: 9066684
    [Abstract] [Full Text] [Related]

  • 18. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.
    Am J Surg Pathol; 2008 Apr 12; 32(4):544-52. PubMed ID: 18300793
    [Abstract] [Full Text] [Related]

  • 19. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
    Castiglioni T, Elsner B, Curutchet HP, Montesinos M, Debonis D.
    Medicina (B Aires); 1995 Apr 12; 55(5 Pt 1):415-20. PubMed ID: 8728771
    [Abstract] [Full Text] [Related]

  • 20. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM.
    Oncol Rep; 2007 Jul 12; 18(1):121-6. PubMed ID: 17549356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.